NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-285-2016-2-SK-01 Glypican 2 As A Cancer Marker And Therapeutic Target SK EP 16864859.0 Issued
NCI E-285-2016-2-PL-01 Glypican 2 As A Cancer Marker And Therapeutic Target PL EP 16864859.0 Issued
NCI E-285-2016-2-MK-01 Glypican 2 As A Cancer Marker And Therapeutic Target MK EP 16864859.0 Issued
NCI E-285-2016-2-RS-01 Glypican 2 As A Cancer Marker And Therapeutic Target RS EP 16864859.0 Issued
NCI E-285-2016-2-MC-01 Glypican 2 As A Cancer Marker And Therapeutic Target MC EP 16864859.0 Issued
NCI E-285-2016-2-NL-01 Glypican 2 As A Cancer Marker And Therapeutic Target NL EP 16864859.0 Issued
NCI E-285-2016-2-MT-01 Glypican 2 As A Cancer Marker And Therapeutic Target MT EP 16864859.0 Issued
NCI E-285-2016-2-RO-01 Glypican 2 As A Cancer Marker And Therapeutic Target RO EP 16864859.0 Issued
NCI E-285-2016-2-DK-01 Glypican 2 As A Cancer Marker And Therapeutic Target DK EP 16864859.0 Issued
NCI E-285-2016-2-EE-01 Glypican 2 As A Cancer Marker And Therapeutic Target EE EP 16864859.0 Issued
NCI E-285-2016-2-AT-01 Glypican 2 As A Cancer Marker And Therapeutic Target AT EP 16864859.0 Issued
NCI E-285-2016-2-BE-01 Glypican 2 As A Cancer Marker And Therapeutic Target BE EP 16864859.0 Issued
NCI E-285-2016-2-AL-01 Glypican 2 As A Cancer Marker And Therapeutic Target AL EP 16864859.0 Issued
NCI E-285-2016-2-DE-01 Glypican 2 As A Cancer Marker And Therapeutic Target DE EP 16864859.0 Issued
NCI E-285-2016-2-HU-01 Glypican 2 As A Cancer Marker And Therapeutic Target HU EP 16864859.0 Issued
NCI E-285-2016-2-SE-01 Glypican 2 As A Cancer Marker And Therapeutic Target SE EP 16864859.0 Issued
NCI E-285-2016-2-ES-01 Glypican 2 As A Cancer Marker And Therapeutic Target ES EP 16864859.0 Issued
NCI E-285-2016-2-BG-01 Glypican 2 As A Cancer Marker And Therapeutic Target BG EP 16864859.0 Issued
NCI E-285-2016-2-HR-01 Glypican 2 As A Cancer Marker And Therapeutic Target HR EP 16864859.0 Issued
NCI E-285-2016-2-CZ-01 Glypican 2 As A Cancer Marker And Therapeutic Target CZ EP 16864859.0 Issued
NCATS E-257-2010-0-US-19 SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS US DIV 15/983,844 10925874 Issued PDF
NCI E-150-2018-0-US-01 CATALYTICALLY HYPERACTIVE VARIANT OF HUMAN APOBEC3G PROTEIN US 62/673,591 Abandoned
NIAID E-136-2013-0-US-06 Single-Domain VHH Antibodies Directed to Norovirus GI.1 And GII.4 And Their Use US DIV 15/982,998 10662238 Abandoned PDF
NCI E-106-2017-0-PCT-02 ANTI-MESOTHELIN POLYPEPTIDES AND PROTEINS (15B6) PCT PCT PCT/US2018/033236 Expired
NHLBI E-219-2018-0-US-01 A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging US 62/672,787 Abandoned
NCI E-099-2014-0-US-09 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND METHODS OF MAKING THEM US CON 15/981,142 10538588 Issued PDF
CC E-158-2017-0-PCT-02 SYSTEMS, METHODS, AND DEVICES FOR ASSISTING OR PERFORMING
GUIDED INTERVENTIONAL PROCEDURES USING INERTIAL MEASUREMENT
UNITS AND MAGNETOMETER SENSORS 		PCT PCT PCT/US2018/033025 Expired
NCI E-017-2017-0-AU-03 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES AU National Stage 2018269194 Issued
NCI E-017-2017-0-JP-07 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES JP National Stage 2019-563082 Issued
NCI E-017-2017-0-CN-05 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES CN National Stage 201880032676.5 Issued
NCI E-017-2017-0-PCT-02 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES PCT PCT PCT/US2018/032809 Expired
NCI E-017-2017-0-EP-06 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES EP National Stage 18733012.1 Pending
NCATS E-114-2018-0-US-01 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS US 62/671,964 Abandoned
NCI E-017-2017-0-CA-04 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES CA National Stage 3062433 Pending
NCI E-001-2016-0-KR-13 Anti-CD30 Chimeric Antigen Receptors KR National Stage 10-2018-7013573 Abandoned
NIDCR E-485-2013-2-US-02 COMPOSITIONS AND METHODS FOR THE INHIBITION OF PRURITUS US ORD 15/979,105 Abandoned
NCI E-010-2016-2-JP-07 Anti-BCMA Polypeptides and Proteins JP National Stage 2018-544769 Issued
NCI E-186-2015-0-US-02 PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE US ORD 15/977,768 10905769 Issued PDF
NCI E-010-2016-2-EP-05 Anti-BCMA Polypeptides and Proteins EP National Stage 16798612.4 Abandoned
NCATS E-095-2018-0-US-01 QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS US 62/670,351 Abandoned
NCI E-010-2016-2-CN-04 Anti-BCMA Polypeptides and Proteins CN National Stage 201680065438.5 Issued
NIAID E-051-2012-3-CN-10 Neutralizing Antibodies To HIV-1 and Their Use CN DIV 201810445511.2 Issued
NCI E-065-2017-0-AU-03 HUMAN MONOCLONAL ANTIBODY TARGETING TNFR2 FOR CANCER IMMUNOTHERAPY AU National Stage 2018268970 Issued
NCI E-139-2015-0-US-04 FIXATIVES AND METHODS OF USE US National Stage 15/774,480 11313772 Issued PDF
NCI E-285-2016-2-JP-05 Glypican 2 As A Cancer Marker And Therapeutic Target JP National Stage 2018-543286 Issued
NCI E-065-2017-0-PCT-02 HUMAN MONOCLONAL ANTIBODY TARGETING TNFR2 FOR CANCER IMMUNOTHERAPY PCT PCT PCT/US2018/031618 Expired
NCI E-127-2017-0-PCT-02 COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES PCT PCT PCT/US2018/031501 Expired
NCI E-065-2017-0-EP-05 HUMAN MONOCLONAL ANTIBODY TARGETING TNFR2 FOR CANCER IMMUNOTHERAPY EP National Stage 18727536.7 Abandoned
NCI E-075-2018-0-US-01 TETRAHEDRAL RNA SCAFFOLD FOR BIOLOGICAL APPLICATIONS US 62/668,653 Abandoned
NCI E-065-2017-0-CA-04 HUMAN MONOCLONAL ANTIBODY TARGETING TNFR2 FOR CANCER IMMUNOTHERAPY CA National Stage 3059472 Pending